$EMBC

HOMBACH ROBERT J. purchased $224K of EMBC

HOMBACH ROBERT J. purchased 45,000 shares of Embecta Corp. (EMBC) at $4.97 ($0.22M total) on 2026-08-12.

Original reporting
SEC EDGAR · HOMBACH ROBERT J.
Published Aug 13, 2026, 2:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 2:49 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$EMBC
Bullish
medium confidence
Mentioned
$EMBC
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EMBCBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase of 45,000 shares at a stated price, which may modestly influence sentiment but does not introduce new business or financial information.

02

Market read

Traders may note the insider buying as a small sentiment input, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The article does not state whether the purchase was part of a broader accumulation strategy, nor does it provide subsequent insider sales or changes in guidance, so traders should avoid over-weighting the signal.

Relevance 5/10Novelty 5/10Timing: filed 2026-08-13, purchase dated 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for Embecta Corp. (EMBC).

Company-level read

Ticker impact

$EMBCBullishMedium confidence
Context

Embecta director Hombach Robert J. bought 45,000 shares of EMBC on 2026-08-12 at $4.9744 per share, per Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small unless followed by additional disclosures.

Evidence & confidence

The filing is primary-source and time-stamped, but the article provides no new company-specific operational or financial development beyond the transaction details.

Market effects

No sector-wide implications; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider purchases under Form 4 can be routine and may not signal improved fundamentals, especially without context like 10b5-1 or prior trading patterns.

Key entities

  • Embecta Corp.

    Company whose insider transaction is disclosed on Form 4.

  • Hombach Robert J.

    Director who purchased 45,000 shares of EMBC on 2026-08-12.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EMBCMedAI 8/10

Embecta (EMBC) Q3 2026 Earnings Call Transcript

Embecta (NASDAQ:EMBC) held its FY2026 Q3 earnings call. Revenue was $271.7M, down 8.1% YoY, with U.S. revenue down 24.6% and international up 11.5% on Owen Mumford strength. Adjusted EPS was $0.56. Free cash flow was $41M. FY2026 guidance: revenue $1.015B-$1.035B, adjusted EPS $1.80-$1.90, margin 23.5%-24%.

$EMBCHighAI 9/10

Embecta (EMBC) Q3 2026 Earnings Call Transcript

Embecta (EMBC) reported Q3 FY2026 revenue of $271.7 million, down 8.1% YoY, with U.S. revenue down 24.6% and international revenue up 11.5%. Adjusted EPS was $0.56. The company raised FY2026 adjusted operating margin guidance to 23.5% to 24% and EPS to $1.80 to $1.90, reaffirming revenue guidance of $1.015B to $1.035B.

$EMBCMed

EMBC Investor Announcement: Embecta Sued on behalf of Investors to Recover Losses after Insulin Pen Issues Lead to 57% Stock Drop

Bleichmar Fonti & Auld LLP said it filed a securities fraud class action against Embecta Corp. (NASDAQ:EMBC) and executives, alleging misleading statements about the strength of its insulin pen needle category. The suit cites a May 5, 2026 stock drop of 57.8% after Q2 results missed guidance, and notes a lead plaintiff deadline of Aug. 17, 2026.

$EMBCMed

Embecta Corp. (EMBC): Results of Operations and Financial Condition

Embecta Corp. (EMBC) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Embecta Corp. Reports Third Quarter Fiscal 2026 Financial Results PARSIPPANY, N.J., Aug 7, 2026 (GLOBE NEWSWIRE) – Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and n

$EMBCMed

$EMBC Notification: Embecta Accused of Misrepresentations about its Insulin Pen Issues in Securities Fraud Class Action

Bleichmar Fonti & Auld LLP said a securities-fraud class action was filed against Embecta Corp. (NASDAQ:EMBC) and executives, alleging misstatements about the strength of its insulin pen needle category. The suit follows Embecta’s May 5, 2026 stock drop of 57.8% after Q2 results missed guidance; the firm cites a dividend cut from $0.15 to $0.01. Lead plaintiff deadline: Aug. 17, 2026.